Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 307
- Registration Number
- NCT03011892
- Locations
- 🇺🇸
HASSMAN RESEARCH INSTITUTE, LLC, 175 Cross Keys Road, Berlin, New Jersey, United States
🇺🇸ACTIVMED PRACTICES & RESEARCH, INC, 138 Conant Street, Beverly, Massachusetts, United States
🇺🇸CENTER FOR CLINICAL STUDIES (CCS), 1401 Binz, Houston, Texas, United States
A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02998476
- Locations
- 🇺🇸
Asclepes Research Centers, Weeki Wachee, Florida, United States
🇺🇸Arizona Oncology Associates, PC - HAL, Tempe, Arizona, United States
🇦🇺Flinders Medical Centre, Bedford Park, South Australia, Australia
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
- Conditions
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 70
- Registration Number
- NCT02959437
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
- Conditions
- Interventions
- First Posted Date
- 2016-11-04
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT02955940
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸New York Oncology Hematology Pc., Clifton Park, New York, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-11-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT02953678
Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)
- Conditions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1469
- Registration Number
- NCT02953704
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 147
- Registration Number
- NCT02924376
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 59
- Registration Number
- NCT02917993
- Locations
- 🇺🇸
Valley Hospital, 223 N Van Dien Avenue, Ridgewood, New Jersey, United States
🇺🇸West Virginia University Cancer Institute, 1 Medical Center Drive, Morgantown, West Virginia, United States
🇺🇸University of Texas -MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas, United States
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 260
- Registration Number
- NCT02903914
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸BIDMC, Boston, Massachusetts, United States
🇺🇸MD Anderson, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)
- First Posted Date
- 2016-08-19
- Last Posted Date
- 2023-03-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 263
- Registration Number
- NCT02872714
- Locations
- 🇩🇪
Klinikum Dresden Standort Dresden-Friedrichstadt, Dresden, Germany
🇩🇪Universitaetsklinikum Carl Gustav Carus TU Dresden, Dresden, Germany
🇩🇪Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany